| Literature DB >> 24287503 |
Peter Rüesch1, René Schaffert, Susanne Fischer, Deb Feldman-Stewart, Robin Ruszat, Peter Spörri, Markus Zurkirchen, Hans-Peter Schmid.
Abstract
PURPOSE: The aims of this study were to analyze agreement on information needs within a group of early-state prostate cancer patients and to compare information preferences of patients with the view of health-care professionals about patients' needs.Entities:
Mesh:
Year: 2013 PMID: 24287503 PMCID: PMC3938857 DOI: 10.1007/s00520-013-2052-8
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Fig. 1Boxplots of number of items judged as “essential”, “desired,” or “avoid”/“no opinion” by patients and health professionals (maximum number of items = 92)
Within- and between-groups agreement of patients and health professionals about information topics on prostate cancer and its treatment
| Chance-corrected agreement | Raw agreement | ||||||
|---|---|---|---|---|---|---|---|
| Kappa (95 % CI) | AC1 (95 % CI) | Overall | _1 | _2 | _3 | _4 | |
| Within groups | |||||||
| Patients | 0.085 (0.067–0.104) | 0.319 (0.277–0.361) | 0.454 | 0.040 | 0.200 | 0.323 | 0.607 |
| Nurses | 0.103 (0.080–0.126) | 0.349 (0.303–0.394) | 0.476 | 0.061 | 0.170 | 0.359 | 0.622 |
| Urologists | 0.146 (0.117–0.175) | 0.295 (0.251–0.338) | 0.447 | 0.103 | 0.266 | 0.408 | 0.576 |
| RTT | 0.090 (0.067–0.112) | 0.398 (0.349–0.447) | 0.507 | 0.071 | 0.105 | 0.320 | 0.666 |
| Oncologists | 0.096 (0.064–0.127) | 0.308 (0.281–0.336) | 0.449 | 0.049 | 0.196 | 0.460 | 0.520 |
| Between pairs of groups | |||||||
| Patient–Nurses | 0.077 (0.057–0.096) | 0.285 (0.242–0.328) | |||||
| Patient–Urologists | 0.096 (0.076–0.116) | 0.282 (0.242–0.322) | |||||
| Patient–RTT | 0.067 (0.050–0.083) | 0.329 (0.287–0.372) | |||||
| Patient–Oncologists | 0.077 (0.058–0.096) | 0.294 (0.264–0.324) | |||||
| Nurses–Urologists | 0.099 (0.081–0.117) | 0.288 (0.249–0.326) | |||||
| Nurses–RTT | 0.087 (0.069–0.105) | 0.363 (0.321–0.404) | |||||
| Nurses–Oncologists | 0.086 (0.066–0.105) | 0.301 (0.273–0.329) | |||||
| Urologists–RTT | 0.091 (0.075–0.108) | 0.292 (0.248–0.336) | |||||
| Urologists–Oncologists | 0.109 (0.089–0.128) | 0.287 (0.258–0.315) | |||||
| RTT–Oncologists | 0.085 (0.069–0.102) | 0.311 (0.281–0.340) | |||||
Answer categories: _1 = “avoid,” _2 = “no opinion,” _3 = “desired,” _4 = “essential”
Kappa unweighted Fleiss’ Kappa, AC1 unweighted Gwet’s AC1 for multiple raters and multiple subjects
Patients’ core set of items (28 out of 92) with high importance as well as high agreement in relation to professionals’ core sets
| Items |
|
| Core sets | Number of sets |
| What is prostate cancer? | 1.90 | 0.85 | I–V | 5 |
| If the prostate cancer is not treated, will I die from it? | 1.75 | 0.67 | I–V | 5 |
| How long can I safely take to make up my mind? | 1.74 | 0.63 | I–V | 5 |
| How long will it take to finish all my treatment? | 1.74 | 0.63 | I–V | 5 |
| If I choose radiation treatment, will I have large areas of my body radiated? | 1.75 | 0.68 | I–V | 5 |
| How does the treatment work? | 1.81 | 0.73 | I–V | 5 |
| When and how will you know if the treatment is working? | 1.80 | 0.71 | I–V | 5 |
| Will the treatment affect my bladder control? If so, for how long? | 1.83 | 0.77 | I–V | 5 |
| What does PSA mean? | 1.79 | 0.73 | I, III–V | 4 |
| If the prostate cancer is not treated, how fast will it spread? | 1.77 | 0.70 | I–IV | 4 |
| If the prostate cancer is not treated, will it be painful? | 1.61 | 0.52 | I–IV | 4 |
| If the prostate cancer is not treated, will it affect my sexual functioning? | 1.59 | 0.51 | I, II, IV, V | 4 |
| What type of monitoring will there be if I choose no treatment? | 1.65 | 0.58 | I–IV | 4 |
| How long will I have to wait to start treatment? | 1.63 | 0.55 | I–IV | 4 |
| What kind of follow-up will take place after my treatment? | 1.57 | 0.51 | I, III–V | 4 |
| Will the treatment affect my sexual functioning? If so, when and for how long? | 1.66 | 0.56 | I, II, III, V | 4 |
| If the prostate cancer is not treated, what parts of my body could be affected? | 1.73 | 0.64 | I–III | 3 |
| If the prostate cancer is not treated, will it affect my bladder functioning? | 1.73 | 0.63 | I, II, IV | 3 |
| If I do not have the treatment now, can I have it when the cancer gets worse? | 1.59 | 0.52 | I, III, V | 3 |
| What do we do if the cancer comes back? | 1.75 | 0.68 | I, II, III | 3 |
| If the treatment is not successful, what are my options? | 1.79 | 0.73 | I, II, III | 3 |
| If I get one type of treatment, can I have any of the other treatments later? | 1.62 | 0.56 | I, III, V | 3 |
| If more than one treatment is needed, how much time does each treatment take? | 1.62 | 0.53 | I, V | 2 |
| When and how will you know if I have been cured? | 1.74 | 0.66 | I, II | 2 |
| If the prostate cancer is not treated, how long will I live? | 1.57 | 0.51 | I | 1 |
| Is the equipment at the hospital up to date for treating the prostate cancer? | 1.59 | 0.52 | I | 1 |
| How experienced is my doctor in treating patients with prostate cancer? | 1.55 | 0.52 | I | 1 |
| Concordance of professionals’ core set with patients’ core set (27 items) | Kappa | Sensitivity, % | Specificity, % | |
| Urologists (28 items) | 0.66 (0.43–0.79) | 74.1 (53.7–88.9) | 87.7 (77.2–94.5) | |
| Nurses (29 items) | 0.54 (0.35–0.73) | 70.4 (49.8–86.2) | 84.6 (73.5–92.4) | |
| RTT (29 items) | 0.38 (0.18–0.59) | 59.3 (38.8–77.6) | 80.0 (68.2–88.9) | |
| Oncologists (22 items) | 0.47 (0.27–0.68) | 55.6 (35.3–74.5) | 89.2 (79.1–95.6) | |
: item mean of patients (−1: “avoid”; 0: “no opinion”; 1: “desired”; 2: “essential”); p i: item-specific raw agreement of patients; core sets: I patients; II nurses; III: urologists; IV RTT; V oncologists
Items belonging to at least one professional core set but not to the patients’ core set
| Items |
|
| Core sets | Number of sets |
|---|---|---|---|---|
| Will I receive medication for symptom control? | 1.46 | 0.44 | II–V | 4 |
| If I choose radiation treatment, should I take hormone pills before the radiation? | 1.54 | 0.54 | III–V | 3 |
| If I delay treatment, is there a chance I can still be cured? | 1.55 | 0.50 | III–V | 3 |
| Will the treatment cause pain? If so, for how long? | 1.55 | 0.49 | II, III, IV | 3 |
| What options/treatments do I have if my impotency is permanent? | 1.56 | 0.50 | II, III, V | 3 |
| If the prostate cancer is not treated, will it disappear on its own? | 1.55 | 0.52 | II, IV | 2 |
| Where will I go for the treatment? | 1.42 | 0.42 | II, IV | 2 |
| Can I continue my exercise program during treatment? | 1.48 | 0.45 | II, IV | 2 |
| Do I continue taking medications (prescribed and over-the-counter) during treatment? | 1.54 | 0.49 | II, IV | 2 |
| If I delay treatment, will any treatment help me? | 1.49 | 0.48 | III, V | 2 |
| Could the treatment lead to my death? | 1.49 | 0.50 | III, V | 2 |
| Are my sons at risk of developing prostate cancer? | 1.08 | 0.32 | III | 1 |
| If the prostate cancer is not treated, will I still be able to carry on my usual activities? | 1.49 | 0.46 | II | 1 |
| Will I get the same level of care regardless of my treatment decision? | 1.32 | 0.39 | V | 1 |
| Can I have sex during the course of treatment? | 1.46 | 0.44 | II | 1 |
| Will I see my doctor during the treatment? | 1.20 | 0.35 | IV | 1 |
| Will I lose my gonads/testicles? | 1.43 | 0.44 | II | 1 |
| Will the treatment make me tired? If so, for how long? | 1.23 | 0.36 | IV | 1 |
| Will the treatment cause diarrhea? If so, for how long? | 1.29 | 0.37 | IV | 1 |
| Will the treatment cause bleeding? If so, for how long? | 1.45 | 0.43 | IV | 1 |
| Will the treatment affect my bowel control? If so, for how long? | 1.45 | 0.44 | IV | 1 |
: item mean of patients (−1: “avoid”; 0: “no opinion”; 1: “desired”; 2: “essential”); p i: item-specific raw agreement of patients; core sets: I patients; II nurses; III: urologists; IV RTT; V oncologists